Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: ‘A new kid on the block’?

References

• Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89:2583–9.
   PubMed Web of Science ®Google Scholar
• Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L, . Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003;138:24–32.
   PubMed Web of Science ®Google Scholar
• Tsigos C, Hainer V, Basdevant A, Finer N, Fried M, Mathus-Vliegen E, . Management of obesity in adults: European Clinical Practice Guidelines. Obesity Management Task Force of the European Association for the Study of Obesity. Obes Facts. 2008;2:106–16.
   Google Scholar
• Eckel RH. Clinical practice. Nonsurgical management of obesity in adults. N Engl J Med. 2008;358:1941–50.
   PubMed Web of Science ®Google Scholar
• DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med. 2007;356:2176–83.
   PubMed Web of Science ®Google Scholar
• James WP. The epidemiology of obesity: the size of the problem. J Intern Med. 2008;263:336–52.
   PubMed Web of Science ®Google Scholar
• ; Look AHEAD Research GroupPi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, . Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30:1374–83.
   PubMed Web of Science ®Google Scholar
• Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, . Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.
   PubMed Web of Science ®Google Scholar
• Marsk R, Freedman J, Tynelius P, Rasmussen F, Näslund E. Antiobesity surgery in Sweden from 1980 to 2005: a population-based study with a focus on mortality. Ann Surg. 2008;248: 777–81.
   PubMed Web of Science ®Google Scholar
• Tice JA, Karliner L, Walsh J, Petersen AJ, Feldman MD. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am J Med. 2008; 121:885–93.
   PubMed Web of Science ®Google Scholar
• Mancini MC, Halpern A. Investigational therapies in the treatment of obesity. Expert Opin Investig Drug. 2006;25: 897–915.
   Google Scholar
• Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag. 2009;5:441–52.
   PubMedGoogle Scholar
• Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin. 2005;21:457–68.
   PubMed Web of Science ®Google Scholar
• Didangelos TP, Thanopoulou AK, Bousboulas SH, Sambanis CL, Athyros VG, Spanou EA, . The ORLIstat and CARdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. Curr Med Res Opin. 2004;20:1393–401.
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.
   PubMed Web of Science ®Google Scholar
• Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2004; (3):CD004094.
   Google Scholar
• Bray GA. Lifestyle and pharmacological approaches to weight loss: efficacy and safety. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S81–8.
   Google Scholar
• Li M, Cheung BM. Pharmacotherapy for obesity. Br J Clin Pharmacol. 2009;68:804–10.
   PubMed Web of Science ®Google Scholar
• Kakafika AI, Mikhailidis DP, Karagiannis A, Athyros VG. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol. 2007;47: 642–52.
   PubMed Web of Science ®Google Scholar
• Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinod-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl). 2009;205:171–4.
   PubMed Web of Science ®Google Scholar
• Czernichow S, Batty D. Withdrawal of sibutramine for weight loss: where does this leave clinicians? Obes Facts. 2010;3:155–6.
   PubMedGoogle Scholar
• Drew BS, Dixon AF, Dixon JB. Obesity management: update on orlistat. Vasc Health Risk Manag. 2007;3:817–21.
   PubMedGoogle Scholar
• Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 2008;31: 53–65.
   PubMed Web of Science ®Google Scholar
• Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, . Rational design of a combination medication for the treatment of obesity. Obesity. 2009; 17:30–9.
   PubMed Web of Science ®Google Scholar
• Whigham LD, Dhurandhar NV, Rahko PS, Atkinson RL. Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status. Int J Obes (Lond). 2007;31:850–7.
   PubMed Web of Science ®Google Scholar
• Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med. 1984;144:1143–8.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res. 2000;8:431–7.
   PubMedGoogle Scholar
• Sari R, Balci MK, Cakir M, Altunbas H, Karayalcin U. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res. 2004;30:159–67.
   PubMed Web of Science ®Google Scholar
• Aydin N, Topsever P, Kaya A, Karasakal M, Duman C, Dağar A. Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? Tohoku J Exp Med. 2004;202:173–80.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Kumar A. Treatment of overweight and obesity: lifestyle, pharmacologic and surgical options. Clin Cornerstone. 2009;9:55–71.
   PubMedGoogle Scholar
• Lee MW, Fujioka K. Naltrexone for the treatment of obesity: review and update. Expert Opin Pharmacother. 2009;10: 1841–5.
   PubMed Web of Science ®Google Scholar
• Plodkowski RA, Nguyen Q, Sundaram U, Nguyen L, Chau DL, Jeor SS. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin Pharmacother. 2009;10:1069–81.
   PubMed Web of Science ®Google Scholar
• Parsons AC, Shraim M, Inglis J, Aveyard P, Hajek P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2009;(1):CD006219.
   Google Scholar
• Greenway FL, Dunayevich E, Tollefson G, Tollefson G, Erickson J, Guttadauria M, . Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab. 2009;94:4898–906.
   PubMed Web of Science ®Google Scholar
• Padwal R. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Curr Opin Investig Drugs. 2009;10:1117–25.
   PubMed Web of Science ®Google Scholar
• Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, . Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.
   PubMed Web of Science ®Google Scholar
• Orexigen® Clinical Trials. Available at: www.orexigen.com/trials/ (accessed 29 September 2010).
   Google Scholar
• Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neill PM, . Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behaviour modification: the COR-BMOD trial. Obesity (Silver Spring). 2010 Jun 17 (Epub ahead of print).
   Google Scholar
• Crosby RD, Kolotkin RL, Williams GR. An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol. 2004;57:1153–60.
   PubMed Web of Science ®Google Scholar
• Hill AJ, Rogers PJ, Blundell JE. Techniques for the experimental measurement of human eating behaviour and food intake: a practical guide. Int J Obes Relat Metab Disord. 1995; 19:361–75.
   PubMedGoogle Scholar
• Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs. 2008;68:653–89.
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Dimitroula HV, Katsiki N, Savopoulos C, Hatzitolios AI. Effects of lifestyle measures, antiobesity agents and bariatric surgery on serological markers of inflammation in obese patients. Mediatotrs Inflamm. 2010;2010: 364957.
   PubMedGoogle Scholar
• Toll BA, Leary V, Wu R, Salovey P, Meandzija B, O'Malley SS. A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. Addict Behav. 2008;33:173–9.
   PubMed Web of Science ®Google Scholar
• Wilcox CS, Oskooilar N, Erickson JS, Billes SK, Katz BB, Tollefson G, . An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict Behav. 2010;35: 229–34.
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol. 2008;23:370–8.
   PubMed Web of Science ®Google Scholar
• Florentin M, Elisaf MS, Mikhailidis DP, Liberopoulos EN. Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome. Curr Pharm Des. 2009;15: 3446–62.
   PubMedGoogle Scholar
• Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, . Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006;22: 873–83.
   PubMed Web of Science ®Google Scholar
• Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol. 2008;126:302–12.
   PubMed Web of Science ®Google Scholar
• Thase ME, Haight BR, Johnson MC, Hunt T, Krishen A, Fleck RJ, . A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol. 2008;28:302–7.
   PubMed Web of Science ®Google Scholar
• James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, . Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Enlg J Med. 2010;363:905–17.
   PubMed Web of Science ®Google Scholar
• Nakou E, Filippatos TD, Liberopoulos EN, Tselepis AD, Kiortsis DM, Mikhailidis DP, . Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin Pharmacother. 2008;9:1629–39.
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Kakafika AI, Athyros VG, Karagiannis A, Mikhailidis DP. The role of statins for the primary and secondary prevention of coronary heart disease in women. Curr Pharm Des. 2009;15:1054–62.
   PubMed Web of Science ®Google Scholar
• Epperson CN, Toll B, Wu R, Amin Z, Czarkowski KA, Jatlow P, . Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug Alcohol Depend. 2010; 112:1–8.
   PubMedGoogle Scholar
• Citrome L. Miracle pills for weight loss: what is the number needed to treat, number neede to harm and likelihood to be helped or harmed for naltrexone-bupropion combination? Int J Clin Pract. 2010;64:1462–5.
   PubMedGoogle Scholar
• Stinton LM, Myers RP, Shaffer EA. Epidemiology of gallstones. Gastroenterol Clin North Am. 2010;39:157–69.
   PubMed Web of Science ®Google Scholar